Evaluation, Staging and Prognostication

Part of the Head and Neck Cancer Clinics book series (HNCC)


The majority of non-melanoma skin cancers (NMSCs), particularly those encountered in primary care settings, will be identified and are easily amenable to local therapy. The most common types of NMSC are basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and rarer tumours, including Merkel cell cancer (MCC) and sarcoma. Metastatic SCC is a rare entity (<5 % of cases); metastatic BCC even more so [1]. However, it is important to identify high-risk patients because of the significant morbidity and mortality experienced by this subgroup of patients. Optimal management of these patients requires multidisciplinary input. Considerable research has been conducted into early identification of such high-risk patients. The initial approach involves a thorough clinical assessment, including detailed history and evaluation of any relevant systemic disease, risk factors and comorbidities, followed by histological analysis. Advanced lesions will require more detailed investigations, including cross-sectional imaging in the form of computed tomography (CT) and or magnetic resonance imaging (MRI). The investigation should not only focus on the primary lesion but also on any potential regional and distant metastatic disease. One approach to the initial assessment of NMSC is shown in Fig. 3.1.


Epidermal Growth Factor Receptor Squamous Cell Carcinoma Basal Cell Carcinoma Perineural Invasion Actinic Keratosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Snow SN, Mohs FE. Metastatic basal cell carcinoma. In: Roenigk RK, Roenigk Jr HH, editors. Surgical dermatology: advances in current practice. London: Martin Dunitz; 1993. p. 109–23.Google Scholar
  2. 2.
    Tufaro AP, Prasad NB, Fischer AC et al. The clinicopathologic and molecular aspects of non-melanoma skin cancer. In: Khopkar U, editor. Skin biopsy: perspectives. InTech; 2011. pp. 197–208. Available at: http://www.intechopen.com/books/skin-biopsy-perspectives/the-clinicopathologic-and-molecular-aspects-of-non-melanoma-skin-cancer.
  3. 3.
    Abbas OL, Borman H. Basal cell carcinoma: a single-center experience. ISRN Dermatol. 2012;2012:246542.PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Raasch BA, Buettner PG, Garbe C. Basal cell carcinoma: histological classification and body-site distribution. Br J Dermatol. 2006;155:401–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Richmond-Sinclair NM, Pandeya N, Ware RS, et al. Incidence of basal cell carcinoma multiplicity and detailed anatomic distribution: longitudinal study of an Australian population. J Invest Dermatol. 2009;129:323–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Callen JP, Bickers DR, Moy RL. Actinic keratoses. J Am Acad Dermatol. 1997;36:650–3.CrossRefPubMedGoogle Scholar
  7. 7.
    Kao GF. Carcinoma arising in Bowen’s disease. Arch Dermatol. 1986;122:1124–6.CrossRefPubMedGoogle Scholar
  8. 8.
    LeBoit PE, Burg G, Weedon D, Sarasain A (eds.). World Health Organization Classification of Tumours. Pathology and Genetics of Skin Tumours. Lyon: IARC Press; 2006.Google Scholar
  9. 9.
    Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001;344:975–83.CrossRefPubMedGoogle Scholar
  10. 10.
    Goh RY, Bova R, Fogarty GB. Cutaneous squamous cell carcinoma metastatic to parotid – analysis of prognostic factors and treatment outcome. World J Surg Oncol. 2012;10:117.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Russell EB, Carrington PR, Smoller BR. Basal cell carcinoma: a comparison of shave biopsy versus punch biopsy techniques in subtype diagnosis. J Am Acad Dermatol. 1999;41:69–71.CrossRefPubMedGoogle Scholar
  12. 12.
    McGuire JF, Ge NN, Dyson S. Nonmelanoma skin cancer of the head and neck I: histopathology and clinical behavior. Am J Otolaryngol. 2009;30:121–33.CrossRefPubMedGoogle Scholar
  13. 13.
    Edge S, Byrd DR, Compton CC, et al. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.Google Scholar
  14. 14.
    Veness MJ, Palme CE, Morgan GJ. High-risk cutaneous squamous cell carcinoma of the head and neck: results from 266 treated patients with metastatic lymph node disease. Cancer. 2006;106:2389–96.CrossRefPubMedGoogle Scholar
  15. 15.
    Kraus DH, Carew JF, Harrison LB. Regional lymph node metastasis from cutaneous squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1998;124:582–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Breuninger H, Black B, Rassner G. Microstaging of squamous cell carcinomas. Am J Clin Pathol. 1990;94:624–7.PubMedGoogle Scholar
  17. 17.
    Geist DE, Garcia-Moliner M, Fitzek MM, et al. Perineural invasion of cutaneous squamous cell carcinoma and basal cell carcinoma: raising awareness and optimizing management. Dermatol Surg. 2008;34:1642–51.PubMedGoogle Scholar
  18. 18.
    Goepfert H, Dichtel WJ, Medina JE, et al. Perineural invasion in squamous cell skin carcinoma of the head and neck. Am J Surg. 1984;148:542–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Moore BA, Weber RS, Prieto V, et al. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope. 2005;115:1561–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Ebrahimi A, Moncrieff MD, Clark JR, et al. Predicting the pattern of regional metastases from cutaneous squamous cell carcinoma of the head and neck based on location of the primary. Head Neck. 2010;32:1288–94.CrossRefPubMedGoogle Scholar
  21. 21.
    Rowe DE, Carroll RJ, Day Jr CL. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992;26:976–90.CrossRefPubMedGoogle Scholar
  22. 22.
    Brantsch KD, Meisner C, Schönfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008;9:713–20.CrossRefPubMedGoogle Scholar
  23. 23.
    Motley R, Kersey P, Lawrence C, British Association of Dermatologists, British Association of Plastic Surgeons, Royal College of Radiologists, Faculty of Clinical Oncology. Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. Br J Dermatol. 2002;146:18–25.CrossRefPubMedGoogle Scholar
  24. 24.
    Martinez JC, Cook JL. High-risk cutaneous squamous cell carcinoma without palpable lymphadenopathy: is there a therapeutic role for elective neck dissection? Dermatol Surg. 2007;33:410–20.PubMedGoogle Scholar
  25. 25.
    Haberal I, Celik H, Göçmen H, et al. Which is important in the evaluation of metastatic lymph nodes in head and neck cancer: palpation, ultrasonography, or computed tomography? Otolaryngol Head Neck Surg. 2004;130:197–201.CrossRefPubMedGoogle Scholar
  26. 26.
    Farasat S, Yu SS, Neel VA, et al. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol. 2011;64:1051–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Jennings L, Schmults CD. Management of high-risk cutaneous squamous cell carcinoma. J Clin Aesthet Dermatol. 2010;3:39–48.PubMedCentralPubMedGoogle Scholar
  28. 28.
    Veness MJ, Morgan GJ, Palme CE, et al. Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice. Laryngoscope. 2005;115:870–5.CrossRefPubMedGoogle Scholar
  29. 29.
    Matthey-Giè ML, Boubaker A, Letovanec I, et al. Sentinel lymph node biopsy in nonmelanoma skin cancer patients. J Skin Cancer. 2013;2013:267474.PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Wagner JD, Evdokimow DZ, Weisberger E, et al. Sentinel node biopsy for high-risk nonmelanoma cutaneous malignancy. Arch Dermatol. 2004;140:75–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Ting PT, Kasper R, Arlette JP. Metastatic basal cell carcinoma: report of two cases and literature review. J Cutan Med Surg. 2005;9:10–5.CrossRefPubMedGoogle Scholar
  32. 32.
    O’Brien CJ, McNeil EB, McMahon JD, et al. Significance of clinical stage, extent of surgery, and pathologic findings in metastatic cutaneous squamous carcinoma of the parotid gland. Head Neck. 2002;24:417–22.CrossRefPubMedGoogle Scholar
  33. 33.
    Palme CE, O’Brien CJ, Veness MJ, et al. Extent of parotid disease influences outcome in patients with metastatic cutaneous squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2003;129:750–3.CrossRefPubMedGoogle Scholar
  34. 34.
    Andruchow JL, Veness MJ, Morgan GJ, et al. Implications for clinical staging of metastatic cutaneous squamous carcinoma of the head and neck based on a multicenter study of treatment outcomes. Cancer. 2006;106:1078–83.CrossRefPubMedGoogle Scholar
  35. 35.
    Oddone N, Morgan GJ, Palme CE, et al. Metastatic cutaneous squamous cell carcinoma of the head and neck. Cancer. 2009;115:1883–91.CrossRefPubMedGoogle Scholar
  36. 36.
    Ch’ng S, Low I, Ng D, et al. Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma. Hum Pathol. 2008;39:344–9.CrossRefPubMedGoogle Scholar

Copyright information

© Faruque Riffat, Carsten E. Palme, Michael Veness, Rehan Kazi, Raghav C. Dwivedi 2015

Authors and Affiliations

  1. 1.Otolaryngology-Head and Neck Surgery, Westmead HospitalUniversity of New South WalesSydneyAustralia
  2. 2.Otolaryngology Head and Neck SurgeryRoyal Prince Alfred Hospital and Westmead HospitalSydneyAustralia
  3. 3.Otolaryngology-Head and Neck SurgeryUniversity of Sydney, Westmead HospitalSydneyAustralia

Personalised recommendations